Shares of Zoetis cratered 6.3% to $72.38 on August 7, bucking a broadly rising market, after the world's largest animal-health company cut its full-year forecast for the second time in three months and admitted its core U.S. pet business is shrinking faster than anticipated. For shareholders who have watched the stock lose 40% year-to-date, the question is no longer about a soft patch — it's whether Zoetis's premium franchise is structurally impaired.

  • Pet Owners Are Pulling Back, and It's Hitting the Biggest Revenue Engine

Q2 revenue of $2.47 billion was essentially flat year-over-year, but underneath, U.S. Companion Animal sales — the segment generating roughly two-thirds of revenue — plunged 11% to $1.04 billion as softer veterinary clinic visits, pet-owner price sensitivity, and intensifying competition in dermatology and flea-and-tick products hammered Zoetis's marquee franchises.

The core dermatology franchise alone fell 16%.

Veterinary clinic visits have been declining for multiple years, a trend that has deepened as prior price increases outpaced broader consumer inflation.

  • The Guidance Cut Is Steep — and It's the Second One This Year

Full-year revenue guidance dropped to $9.12–$9.32 billion, down from the prior range of $9.68–$9.96 billion, while adjusted EPS was slashed to $6.15–$6.25 from $6.85–$7.00.

Zoetis now expects organic revenue to shrink 1–3% and adjusted net income to fall 5–9% — a jarring reversal for a company that long commanded a premium valuation on the promise of steady mid-single-digit growth.

  • Competitors Are Playing Rougher, and Zoetis Is Fighting Back With Discounts

CEO Kristin Peck acknowledged "the nature of competition has changed," with rivals using aggressive discounting, rebates, and cross-portfolio bundling to seize market share.

In response, Zoetis is deploying time-bound rebates and point-of-sale promotions rather than permanent list-price cuts — a strategy that preserves sticker prices but pressures margins nonetheless.

  • Livestock and Diagnostics Are Bright Spots, but Not Big Enough

A 23% surge in U.S. Livestock revenue and 8% international growth cushioned the blow but couldn't fully offset domestic companion-animal weakness.

The damage is reflected in Zoetis's June removal from the Russell Top 200 index and reclassification into the Russell Midcap — a symbolic demotion that underscores how far the company has fallen from its former large-cap status. Until U.S. pet-health trends stabilize, every earnings report is a referendum on whether Zoetis can defend a franchise that investors once considered unassailable.